Phosphatidylserine Cortisol Blunting Research

---

Table of Contents

1. What Is Phosphatidylserine and Why Does Cortisol Matter?
2. How Phosphatidylserine Interacts With the HPA Axis
3. The Key Clinical Studies on Phosphatidylserine Cortisol Blunting
4. Exercise Stress vs. Psychological Stress: Where Is the Evidence Stronger?
5. Dosing: What the Research Actually Used
6. Soy-Derived vs. Bovine-Derived PS: Does the Source Matter?
7. How Fast Does Phosphatidylserine Work?
8. Does PS Lower Baseline Cortisol or Only Stress-Induced Spikes?
9. What 2024–2026 Reviews Say About the Evidence
10. Common Questions About PS and Cortisol
11. Safety and Daily Use Considerations
12. Summary: What the Phosphatidylserine Cortisol Evidence Shows

---

What Is Phosphatidylserine and Why Does Cortisol Matter?

Phosphatidylserine (PS) is a phospholipid — a fat-soluble molecule with a phosphate group head — that forms a critical structural component of cell membranes throughout the human body. It is particularly concentrated in neural tissue, where it plays roles in cell signaling, membrane fluidity, and receptor function. While it is naturally synthesized in the body and present in small amounts in dietary sources like white beans, soy lecithin, and organ meats, PS levels decline with age and are difficult to replenish through diet alone at the concentrations used in clinical research.

Cortisol, on the other hand, is the primary glucocorticoid hormone produced by the adrenal cortex. It is released in response to physical or psychological stressors through a cascade involving the hypothalamus, the pituitary gland, and the adrenal glands — a pathway called the hypothalamic-pituitary-adrenal axis, or HPA axis. In the short term, cortisol is adaptive: it mobilizes energy, suppresses inflammation, and sharpens alertness. But when stress is chronic or intense — as it commonly is in athletes during overtraining, in people with high work-related stress, or in anyone experiencing prolonged psychological pressure — sustained cortisol elevation can impair immune function, disrupt sleep, accelerate muscle catabolism, increase visceral fat deposition, and interfere with mood and cognition.

This is precisely why phosphatidylserine cortisol research has attracted so much attention. If a phospholipid supplement could modulate the HPA axis and reduce excessive cortisol secretion without the side effects of pharmaceutical cortisol modulators, it would represent a genuinely useful tool for athletes, high-stress professionals, and anyone seeking to protect long-term health from cortisol-related wear.

The question this article addresses is not whether this idea is plausible — it is — but whether the evidence actually supports it, how strong that evidence is, and what practical conclusions can reasonably be drawn from it.

---

---

How Phosphatidylserine Interacts With the HPA Axis

Understanding phosphatidylserine HPA interactions requires a brief look at how the stress response cascade actually works.

When the brain perceives a stressor — whether that is a heavy squat session, a public speaking engagement, or a psychological threat — the hypothalamus releases corticotropin-releasing hormone (CRH). CRH travels to the anterior pituitary, where it stimulates the release of adrenocorticotropic hormone (ACTH). ACTH then travels through the bloodstream to the adrenal cortex, where it triggers cortisol synthesis and secretion. Cortisol then feeds back negatively to both the hypothalamus and the pituitary to suppress further CRH and ACTH release — this is the negative feedback loop that normally keeps cortisol in check.

The proposed mechanism by which PS modulates this system involves phospholipid-mediated effects on membrane receptor sensitivity and intracellular signaling within the HPA axis itself. Several lines of evidence suggest that PS supplementation may:

• Enhance negative feedback sensitivity at the level of the pituitary and hypothalamus, meaning the stress hormone cascade is dampened more efficiently
• Modulate glucocorticoid receptor activity, which affects how readily cortisol's own signal suppresses further ACTH release
• Influence neurotransmitter activity, particularly acetylcholine and dopamine systems, which have modulatory effects on HPA axis tone
• Reduce pro-inflammatory cytokine activity, since cytokines such as IL-6 are known drivers of HPA stimulation during exercise and illness

It is worth emphasizing that these mechanisms are not fully characterized at a molecular level in humans. Much of the mechanistic work comes from animal studies and cell culture research. What the human clinical literature provides is evidence about outcomes — ACTH levels, cortisol levels, salivary cortisol, and related markers — rather than a complete mechanistic picture of why those outcomes occur.

What makes PS HPA research particularly interesting is that ACTH is measured alongside cortisol in the most well-designed studies. If PS were merely acting as a downstream cortisol scavenger or interfering with cortisol measurement (an artifact), you would not expect ACTH to be affected. The fact that several studies show ACTH suppression alongside cortisol suppression suggests the effect, where it exists, is genuinely operating upstream in the HPA axis.

---

The Key Clinical Studies on Phosphatidylserine Cortisol Blunting

This is the core of the article. PS cortisol research has a surprisingly long history — the first major controlled trial was published in 1992 — but the total number of high-quality randomized controlled trials remains small. Here is a systematic look at the most cited studies.

The 1992 Monteleone Study: The Foundational Evidence

The landmark early study on phosphatidylserine cortisol blunting was published in 1992 by Monteleone and colleagues. In a placebo-controlled crossover design involving 9 healthy men, participants received bovine-derived phosphatidylserine at 800 mg per day for 10 days before undergoing a standardized physical exercise stress test.

The results were striking for a supplement study of this era:

• ACTH response was significantly blunted (P = 0.003)
• Cortisol response was significantly blunted (P = 0.03)

The fact that both ACTH and cortisol were suppressed was important, as noted above, because it pointed to an effect occurring at the level of the pituitary or hypothalamus rather than purely at the adrenal gland. This study became one of the most frequently cited pieces of phosphatidylserine cortisol evidence and established the biological plausibility of the entire area of inquiry.

The limitations were also significant: only 9 participants, a crossover design that requires careful period washout management, bovine-derived PS that is no longer commercially standard, and a relatively short 10-day supplementation window.

The 2004 Hellhammer Study: Psychological Stress and Soy-Based PS

A 2004 study by Hellhammer and colleagues examined a soy lecithin-derived phosphatidic acid and phosphatidylserine (PAS) complex at 400 mg per day. Rather than physical exercise, this study used the Trier Social Stress Test (TSST) — a validated laboratory psychological stressor involving public speaking and mental arithmetic in front of evaluators — as the stressor.

Results showed that the PAS complex reduced ACTH and cortisol responses to the TSST, including reductions in salivary cortisol, compared to placebo. This study was notable because it demonstrated that the cortisol-blunting effect was not limited to physical exercise stress and could extend to psychosocial stressors. It also used a soy-derived formulation, which was relevant for the growing commercial market that had shifted away from bovine brain-derived PS.

The 2008 Starks Study: Quantifying the Magnitude

The 2008 study by Starks and colleagues is often cited because it provides the clearest numerical quantification of the phosphatidylserine exercise cortisol effect. In this exercise-stress trial, participants received 600 mg per day of soy-derived PS (S-PS) for 10 days before completing a standardized exercise protocol.

The findings:

• Mean peak cortisol concentrations were reduced by 39% versus placebo
• Cortisol area under the curve (AUC) was reduced by 35% versus placebo
• Both effects reached statistical significance (P < 0.05)

A 39% reduction in peak cortisol is a large effect size for a supplement intervention. However, the sample size and design details of this study have been scrutinized. Critics note that small sample sizes make large effect sizes less reliable and more susceptible to noise. Nonetheless, this study remains one of the most frequently cited data points in PS stress research and is regularly referenced in both academic reviews and consumer-facing summaries.

The 2014 Hellhammer Study: Stressed vs. Non-Stressed Subjects

A particularly important refinement came from a 2014 study (also from the Hellhammer group) that examined 400 mg per day of a PAS complex in subjects stratified by their chronic stress levels.

The critical finding: PS normalized ACTH, salivary cortisol, and serum cortisol responses to stress in chronically high-stressed subjects, but the effect was not seen in low-stressed subjects.

This conditional finding is extremely practically important. It suggests that phosphatidylserine stress response modulation may be most relevant — and perhaps only relevant — in individuals who are genuinely experiencing elevated or dysregulated stress responses. For people with normal, well-regulated cortisol responses, PS may not produce a measurable effect. This would explain some of the inconsistency across studies: if a given trial's participants are not particularly stressed, the effect may simply not emerge.

This finding also has implications for athletic use: an athlete in an overreaching training block with elevated chronic stress markers might respond differently to PS than a recreational exerciser with normal HPA tone.

---

---

Exercise Stress vs. Psychological Stress: Where Is the Evidence Stronger?

When reviewing phosphatidylserine cortisol studies as a whole, it is reasonable to ask whether the evidence is more consistent for physical (exercise) stressors or psychological stressors.

For exercise stress: The 1992 Monteleone study and the 2008 Starks study both used exercise stress protocols and both found significant cortisol and ACTH blunting. The consistency of these findings across two independent groups with different dosing (800 mg vs. 600 mg) and different decades adds some credibility.

For psychological stress: The 2004 and 2014 Hellhammer studies used the TSST and showed cortisol blunting, particularly in high-stressed individuals. The 2014 conditional finding (effect only in high-stressed subjects) is noteworthy.

However, a critical counterpoint comes from a 2024 EBSCO Research Starters review, which concluded that only two double-blind placebo-controlled studies on PS as a sports supplement had been reported, and that neither found statistically significant effects on cortisol levels. This apparent contradiction with the studies summarized above likely reflects differences in how studies are classified (sports supplement studies vs. clinical stress studies), the specific outcomes measured, and the populations studied.

The honest summary is: the evidence for phosphatidylserine exercise cortisol blunting is positive but based on very few small studies. The signal is there, but it is not robust by the standards required to call something conclusively proven. Psychological stress research shows similarly promising but limited evidence, with the critical caveat that baseline stress level may be a moderating variable.

Neither domain has enough large, well-powered, independently replicated trials to call this settled science. That does not mean the effect does not exist — it means the evidence base is not yet as strong as the enthusiasm for PS in performance and wellness communities might suggest.

---

Dosing: What the Research Actually Used

One of the most common questions in PS cortisol research is what dose is actually supported by the studies. Here is what the evidence shows:

| Study | Dose | Duration | Stressor Type | Outcome | |-------|------|----------|---------------|---------| | Monteleone 1992 | 800 mg/day (bovine PS) | 10 days | Exercise | Significant ACTH ↓, cortisol ↓ | | Hellhammer 2004 | 400 mg/day (soy PAS complex) | Not specified | Psychological (TSST) | Significant ACTH ↓, cortisol ↓ | | Starks 2008 | 600 mg/day (soy PS) | 10 days | Exercise | Cortisol peak ↓ 39%, AUC ↓ 35% | | Hellhammer 2014 | 400 mg/day (soy PAS complex) | Not specified | Psychological (TSST) | Cortisol ↓ in high-stressed only |

The dosing range across studies spans 400 mg to 800 mg per day. Most contemporary PS supplements are formulated at 100 mg per serving, meaning that to reach the 400–600 mg doses used in research, users would need to take 4–6 capsules per day — something many product labels do not make explicit.

It is also worth noting that some studies used a phosphatidic acid/phosphatidylserine (PAS) complex rather than pure PS. Phosphatidic acid is a related phospholipid with its own signaling properties, and it is not clear whether the effects seen in PAS studies should be attributed entirely to the PS component.

For the phosphatidylserine cortisol blunting effect specifically, most reviewers point to 400–600 mg/day as the practical target range, with some older studies using 800 mg/day without apparent safety concerns.

---

Soy-Derived vs. Bovine-Derived PS: Does the Source Matter?

This question matters both scientifically and practically. Early research — including the foundational 1992 Monteleone study — used bovine cortex-derived PS. This form is no longer commercially available in most markets due to concerns about bovine spongiform encephalopathy (BSE, or "mad cow disease"), which emerged in the 1990s and drove manufacturers to shift to plant-based sources.

Modern PS supplements are almost universally derived from soy lecithin or, more recently, from sunflower lecithin. These sources produce PS with a somewhat different fatty acid profile compared to bovine cortex PS:

• Bovine PS is rich in docosahexaenoic acid (DHA) and arachidonic acid in its fatty acid chains
• Soy PS is primarily composed of linoleic acid and other omega-6 fatty acids
• Sunflower PS has a similar profile to soy but is used as an alternative for those with soy allergies

Whether this fatty acid compositional difference affects bioactivity is a legitimate scientific question. Some researchers have argued that the DHA-rich composition of bovine PS made it more bioactive in neural tissue, and that soy PS may be less effective. However, the Starks 2008 and Hellhammer 2004/2014 studies all used soy-derived formulations and still found cortisol effects, so soy PS is not without evidence. The 2008 Starks study used explicitly labeled soy-derived PS (S-PS) at 600 mg/day and still achieved a 39% reduction in peak cortisol — arguably the largest effect size in any PS cortisol study.

The honest answer is that we do not yet have a head-to-head randomized trial comparing bovine and soy PS for cortisol outcomes in the same population with the same stressor protocol. Until such data exist, claiming definitively that one source is superior remains speculative.

---

How Fast Does Phosphatidylserine Work?

Based on the available PS stress research, the loading period used across studies was consistently 10 days in exercise trials, with the Hellhammer psychological stress studies not always specifying exact duration.

Phosphatidylserine is a membrane phospholipid, and its incorporation into cell membranes — particularly neural membranes — requires time. This is not a stimulant that produces acute effects within hours of ingestion. The 10-day supplementation period used in exercise studies suggests that researchers expected a loading period to be necessary, and the significant results at 10 days support this assumption.

Whether a longer loading period (e.g., 4–6 weeks) would produce larger or more consistent effects is not well studied. Some animal research suggests that longer-term supplementation may produce more pronounced neurochemical changes, but translating this to human HPA axis outcomes requires clinical trials that have not been conducted.

Practical takeaway: Based on current evidence, expect a minimum of 7–10 days of consistent supplementation before expecting measurable effects on stress-induced cortisol responses. This is consistent with how most phospholipid-based supplements behave physiologically.

---

---

Does PS Lower Baseline Cortisol or Only Stress-Induced Spikes?

This is one of the most practically important questions in the phosphatidylserine cortisol evidence literature, and the answer matters enormously for who is most likely to benefit.

The short answer: the evidence is almost entirely for stress-induced cortisol elevation, not resting baseline cortisol.

Every major study in this area measured cortisol responses to an acute stressor — either physical exercise or a psychological stress test — rather than tracking 24-hour cortisol profiles or waking cortisol levels under resting conditions. The finding that the 2014 Hellhammer study showed no effect in low-stressed subjects reinforces the interpretation that PS does not simply suppress cortisol indiscriminately. Rather, it appears to modulate the amplitude of the cortisol stress response — the spike — rather than shifting the entire cortisol baseline downward.

This is actually a favorable pharmacological profile in many ways. Cortisol is not uniformly harmful. Its natural diurnal variation — high in the morning, declining through the day — is important for metabolic function, immune regulation, and energy. A supplement that flattened cortisol completely would likely have negative consequences. A supplement that prevents excessive stress-induced cortisol spikes without disrupting baseline rhythms is a more refined and arguably more useful intervention.

However, this means that someone hoping to lower chronically elevated morning cortisol, or to address elevated 24-hour urine cortisol as seen in certain medical conditions, should not expect PS to address those situations in the way clinical therapies would. As 2026 clinical summaries have noted, PS is not a proven treatment for true hypercortisolism or consistently high cortisol, and the evidence is strongest for small stress-response modulation rather than daily cortisol control.

---

What 2024–2026 Reviews Say About the Evidence

The most recent synthesis of the PS cortisol research literature provides important context for interpreting the positive individual studies.

2024: An EBSCO Research Starters article on phosphatidylserine concluded that only two double-blind placebo-controlled sports-supplement studies had been reported, and that neither found statistically significant effects on cortisol levels. This is a notably different conclusion from what the individual studies summarized above might suggest. The discrepancy likely reflects the strict methodological criteria applied by the EBSCO review — double-blind, placebo-controlled, sports supplement context — which may exclude some of the positive studies based on design features.

2026: Multiple current summaries and reviews reiterate that PS may modestly blunt stress-related cortisol responses, especially in exercise settings, but evidence remains limited and is not strong for lowering baseline cortisol across the board.

2026: A recent review-style article summarized earlier trials as showing that 600–800 mg/day can reduce exercise-induced cortisol elevation, while noting weak evidence for performance and body-composition benefits. The implication is that cortisol blunting may be a real but relatively isolated effect that does not automatically translate into meaningful improvements in athletic performance metrics.

2026: Another current clinical summary stated that PS is not a proven treatment for true hypercortisolism or consistently elevated cortisol, and that evidence is strongest for small stress-response changes rather than daily cortisol control.

What these reviews collectively suggest is a picture of a supplement with genuine biological plausibility and some positive clinical evidence, but a relatively thin evidence base that is insufficient to make strong clinical recommendations. The total number of well-controlled human trials remains small, most individual studies have sample sizes under 20 participants, and independent replication of key findings is limited.

This does not mean PS is ineffective. It means that the enthusiasm for phosphatidylserine cortisol blunting in the performance and wellness community has outpaced the evidence base — a common situation with nutraceuticals that have early promising findings.

---

Common Questions About PS and Cortisol

Does phosphatidylserine really lower cortisol?

The evidence suggests it can reduce stress-induced cortisol spikes, particularly in the context of exercise and psychosocial stressors, at doses of 400–800 mg/day over at least 10 days. The effect appears more consistent in individuals with higher baseline stress levels. It does not reliably lower resting cortisol levels, and recent systematic reviews applying strict methodological criteria have not confirmed the effect across all studies. So the honest answer is: probably yes, under certain conditions, modestly.

What dose is used in studies for cortisol blunting?

Studies have used 400 mg/day (Hellhammer 2004, 2014), 600 mg/day (Starks 2008), and 800 mg/day (Monteleone 1992). The 400–600 mg range is most commonly referenced for practical recommendations. Many commercial supplements provide 100–200 mg per serving, so achieving research-level doses requires multiple servings daily.

Is it more effective for exercise stress or psychological stress?

Both have evidence. The exercise studies (Monteleone 1992, Starks 2008) showed strong cortisol and ACTH blunting. The psychological stress studies (Hellhammer 2004, 2014) also showed effects, particularly in high-stressed individuals. Neither domain has definitively stronger evidence given the small number of studies in each.

How fast does phosphatidylserine work?

Based on the research, the studies that showed cortisol blunting used supplementation periods of at least 10 days before testing. PS is a structural phospholipid that requires incorporation into membranes over time; it is not a fast-acting stimulant or adaptogen. Expect 7–14 days minimum before effects on cortisol responses might be measurable.

Does it lower baseline cortisol or only stress-induced spikes?

Almost exclusively stress-induced spikes based on current evidence. No well-designed study has shown reliable reductions in resting or diurnal baseline cortisol levels. The 2014 Hellhammer study's finding that effects only occurred in high-stressed subjects further supports the idea that PS modulates the stress response rather than suppressing cortisol generally.

Is soy-derived PS different from bovine-derived PS?

Yes, compositionally — soy PS has a different fatty acid profile than bovine cortex PS. However, soy PS studies (Starks 2008, Hellhammer 2004/2014) have also shown cortisol-blunting effects, so soy PS is not without evidence. Bovine PS is no longer commercially available due to BSE concerns. Sunflower-derived PS is a newer alternative with a similar profile to soy PS but without soy allergen concerns.

Is phosphatidylserine safe for daily use?

At doses up to 800 mg/day for periods studied (10 days to several weeks), PS has been well tolerated in clinical trials with no serious adverse events reported. PS is an endogenous phospholipid present in human cell membranes, and supplemental doses are generally considered to add to a naturally occurring pool. Long-term safety data beyond several weeks are limited. Individuals taking anticoagulants should consult a physician, as PS may have mild antiplatelet properties.

Can it help with sleep, anxiety, or recovery if cortisol is high?

Indirectly, if elevated cortisol is contributing to these issues. High cortisol, particularly in the evening when it should be low, can disrupt sleep architecture. If PS reduces stress-induced cortisol elevation during evening hours, improved sleep might follow. However, no clinical trials have specifically measured sleep, anxiety scores, or recovery metrics as primary outcomes in the context of PS supplementation, so these connections remain inferential.

Does it improve athletic performance or only cortisol markers?

Recent 2026 reviews note weak evidence for performance and body-composition benefits specifically, even in studies where cortisol markers improved. Reducing cortisol alone does not guarantee improved athletic outcomes. Performance depends on many variables, and blunting a cortisol response does not automatically translate to faster times, greater strength, or improved body composition.

---

Safety and Daily Use Considerations

The safety profile of phosphatidylserine is generally considered favorable, particularly given its status as an endogenous membrane component. Across the clinical studies reviewed above — spanning doses from 400 to 800 mg/day and durations of 10 days to several weeks — no serious adverse effects were reported.

Reported minor effects in some studies:

• Mild gastrointestinal discomfort at higher doses (800 mg/day)
• Loose stools at high doses in some individuals

Potential interactions to consider:

• Anticoagulants/antiplatelet agents: PS may mildly affect platelet aggregation; individuals on warfarin, aspirin, or other blood thinners should consult a physician before use
• Anticholinergic medications: Given PS's proposed effects on acetylcholine neurotransmission, theoretical interactions exist, though no clinical case reports of harm have been published
• Cognitive-enhancing medications: PS is sometimes combined with other nootropics; combination effects are not well studied

Regulatory note: In the United States, the FDA has issued a qualified health claim for PS, specifically stating that "consumption of phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly" and "may reduce the risk of dementia in the elderly" — though these claims are qualified because evidence is limited. This claim relates to cognitive outcomes, not cortisol or stress specifically.

Populations without established safety data:

• Pregnant or breastfeeding women
• Children
• Individuals with autoimmune conditions (given PS's role in apoptotic signaling)

For healthy adults using PS at 400–600 mg/day for stress and cortisol management, the available evidence suggests an acceptable safety profile for short-to-medium-term use. Long-term studies (beyond 3–6 months) are not available, so caution is warranted for indefinite continuous use without periodic reassessment.

---

---

Summary: What the Phosphatidylserine Cortisol Evidence Shows

After reviewing all available phosphatidylserine cortisol evidence — from the foundational 1992 Monteleone study through 2026 systematic reviews — the following conclusions are reasonably well supported:

What the evidence supports:

1. PS can blunt stress-induced ACTH and cortisol responses in controlled laboratory settings, as shown by multiple independent research groups using different stressor types (exercise and psychological stress)

1. The effect operates at the level of the HPA axis, as indicated by ACTH suppression occurring alongside cortisol suppression

1. The effect is most consistent in individuals with elevated chronic stress, as the 2014 study showed effects only in high-stressed, not low-stressed, participants

1. Doses of 400–800 mg/day for at least 10 days are what the evidence supports; lower doses and shorter durations used in many commercial contexts are not well validated

1. Both bovine and soy-derived PS have shown effects, though the total evidence base for each source is small

What the evidence does not support:

1. PS does not reliably lower baseline or resting cortisol levels in individuals without elevated stress responses

1. PS is not a proven performance enhancer — cortisol reductions have not consistently translated to improved athletic performance metrics

1. PS is not a treatment for hypercortisolism or clinical cortisol dysregulation — it is not in the same category as pharmaceutical interventions for adrenal disorders

1. The evidence base remains thin — the total number of well-controlled, adequately powered human trials is small, and the 2024 EBSCO review's conclusion that sports-supplement studies specifically have not found cortisol effects underscores the limitations

The bottom line on phosphatidylserine stress research:

PS is a biologically plausible and reasonably well-tolerated phospholipid supplement with early but limited evidence for modulating HPA axis responses to acute stress. It is most likely to be useful for individuals with genuinely elevated stress responses — whether from intense exercise training, psychological stressors, or chronic high-demand environments — who are using adequately dosed products (400–600 mg/day minimum) over a sufficient loading period.

For those populations, the phosphatidylserine cortisol blunting research is suggestive enough to consider as part of a broader recovery and stress-management strategy. For individuals with normal, well-regulated stress responses, the evidence does not support expecting meaningful cortisol-lowering effects.

The field needs larger, independently conducted, pre-registered trials with adequate power and clearly defined populations before stronger recommendations can be made. Until then, PS sits in the category of "promising, plausible, and reasonably safe, but not yet conclusively proven."

---

This article is for informational purposes and reviews published research on phosphatidylserine and cortisol. It is not medical advice, does not constitute a diagnosis, and should not replace consultation with a qualified healthcare provider. Individuals with medical conditions affecting cortisol regulation should seek professional medical evaluation.

---

References cited in this article:

1. Starks et al. (2008) — Exercise-induced cortisol, S-PS 600 mg/day
2. Monteleone et al. (1992) — ACTH and cortisol blunting, 800 mg/day PS
3. 2026 review summaries on PS and exercise cortisol
4. Hellhammer et al. (2004) — PAS complex and TSST
5. Hellhammer et al. (2014) — Stressed vs. non-stressed populations
6. 2026 clinical summaries on PS limitations
7. EBSCO Research Starters (2024) — Double-blind sports supplement review
8. 2026 clinical summaries on PS and hypercortisolism